BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study

Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a Phase III study that combined either therapy with doxorubicin, vinblastine and dacarbazine.